Former Lundbeck CEO: Voicing public opinions isn't always prudent

With his 70th birthday coming up Sunday: Anders Gersel Pedersen stayed for longer at Lundbeck than he had expected. He's now a professional member of the board.

Photo: Lundbeck / PR

Former Lundbeck Chief Executive Anders Gersel Pedersen, M.D., Ph.D, would like to have left as managing figure in the pharmaceutical company some time before he actually did.

Today, he's a professional member of the board with posts in, among others, biotechnology company Genmab and Bavarian Nordic. For more than a decade, however, he served as executive vice president and head of research and development at Lundbeck, a position he left in the beginning of 2019.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs